Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 27;20(1):107.
doi: 10.1186/s12875-019-0986-8.

Effectiveness of training general practitioners to improve the implementation of brief stop-smoking advice in German primary care: study protocol of a pragmatic, 2-arm cluster randomised controlled trial (the ABCII trial)

Affiliations

Effectiveness of training general practitioners to improve the implementation of brief stop-smoking advice in German primary care: study protocol of a pragmatic, 2-arm cluster randomised controlled trial (the ABCII trial)

Sabrina Kastaun et al. BMC Fam Pract. .

Abstract

Background: The German clinical guideline on tobacco addiction recommends that general practitioners (GPs) provide brief stop-smoking advice to their patients according to the "5A" or the much briefer "ABC" method, but its implementation is insufficient. A lack of training is one barrier for GPs to provide such advice. Moreover, the respective effectiveness of a 5A or ABC training regarding subsequent delivery of stop-smoking advice has not been investigated. We developed a training for GPs according to both methods, and conducted a pilot study with process evaluation to optimize the trainings according to the needs of GPs. This study aims at evaluating the effectiveness of both trainings.

Methods: A pragmatic 2-arm cluster randomised controlled trial with a pre-post data collection will be conducted in 48 GP practices in North Rhine-Westphalia (Germany). GPs will be randomised to receive a 3.5-h-training in delivering either 5A or ABC, including peer coaching and intensive role plays with professional actors. The patient-reported primary outcome (receipt of GP advice to quit: yes/no) and secondary outcomes (recommendation rates of smoking cessation treatments, group comparison (5A versus ABC): receipt of GP advice to quit) will be collected in smoking patients routinely consulting their GP within 4 weeks prior, and 4 weeks following the training. Additional secondary outcomes will be collected at 4, 12 and 26 weeks following the consultation: use of cessation treatments during the last quit attempt (if so) since the GP consultation, and point-prevalence abstinence rates. The primary data analysis will be conducted using a mixed-effects logistic regression model with random effects for the cluster variable.

Discussion: If the training increases the rates of delivery of stop-smoking advice, it would offer a low-threshold strategy for the guideline implementation in German primary care. Should one method prove superior, a more specific guideline recommendation can be proposed.

Trial registration: German Clinical Trials Register (DRKS00012786); registered on 22th August 2017, prior to the first patient in.

Keywords: Brief smoking cessation advice; General practitioner; National practice guideline; Primary care; Tobacco addiction.

PubMed Disclaimer

Conflict of interest statement

SK, VL, JH, CF, SB, DL, OR, WV, and LH have no conflict of interest to declare.

DK received an unrestricted grant from Pfizer in 2009 for an investigator-initiated trial on the effectiveness of practice nurse counselling and varenicline for smoking cessation in primary care (Dutch Trial Register NTR3067). HM has received honoraria for speaking at smoking cessation meetings and attending advisory board meetings that have been organised by Pfizer and Johnson & Johnson. TR has received honoraria from Pfizer, Novartis, Glaxo Smith Kline, Astra Zeneca and Roche as a speaker in activities related to continuing medical education. He has also received financial support for investigator-initiated trials from Pfizer and Johnson & Johnson. RW has undertaken research and consultancy for companies that develop and manufacture smoking cessation medications (Pfizer, Johnsons & Johnson, and Glaxo Smith Kline). He is an advisor to the UK’s National Centre for Smoking Cessation and Training. All authors declare no financial links with tobacco companies or e-cigarette manufacturers or their representatives.

Figures

Fig. 1
Fig. 1
Gantt chart of the study illustrating the schedule of the total study, including the preparation period, pilot testing of the intervention, the distribution of the six study cycles (intervention) over the total duration of the study, and all periods of data collection. P0 Process evaluation pilot study, finalisation of training and manual, ethical approval, study registration. P1-P6 Preparations study cycles 1 to 6: practice recruitment, material, application for CME certification, scheduling of trainings. B1-B6 Pre- (7 days) and post-baseline (7 days) data collection of primary and secondary outcomes (S1-S3) in 8 GP practices per study cycle. T1-T6 Intervention: 3.5-h training of GPs in delivering brief stop-smoking advice according to either 5A or ABC. F1-F6 Postal follow-up data collection of secondary outcomes (S4-S9) corresponding to study cycle 1–6
Fig. 2
Fig. 2
Consolidated Standards of Reporting Trials (CONSORT) flow chart illustrating all steps in the study from enrolment to training allocation and follow-ups. Inclusion and exclusion criteria are also specified as well as outcome measures

References

    1. Mons U, Brenner H. Demographic ageing and the evolution of smoking-attributable mortality: the example of Germany. Tob Control. 2017;26:455–457. doi: 10.1136/tobaccocontrol-2016-053008. - DOI - PubMed
    1. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-century hazards of smoking and benefits of cessation in the United States. New Engl J Med. 2013;368:341–350. doi: 10.1056/NEJMsa1211128. - DOI - PubMed
    1. European Commission . Special Eurobarometer 458. 2017.
    1. Kotz D, Boeckmann M, Kastaun S. The use of tobacco, E-cigarettes, and methods to quit smoking in Germany. Dtsch Arztebl Int. 2018;115:235–242. - PMC - PubMed
    1. Mackenbach JP, Stirbu I, Roskam AJ, Schaap MM, Menvielle G, Leinsalu M, et al. Socioeconomic inequalities in health in 22 European countries. N Engl J Med. 2008;358:2468–2481. doi: 10.1056/NEJMsa0707519. - DOI - PubMed

Publication types

Associated data